Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase I/II Investigation of Temsirolimus Plus Lenalidomide in Relapsed Non-Hodgkin Lymphomas

NCT01076543 is registered in ClinicalTrials.gov with National Cancer Institute (NCI) as lead sponsor.

NCT NCT01076543
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01076543 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase I/II Investigation of Temsirolimus Plus Lenalidomide in Relapsed Non-Hodgkin Lymphomas
Lead sponsor
National Cancer Institute (NCI)
Phase
Phase 1/2
Overall status
Completed
Start date
April 15, 2010
Completion date
September 30, 2018
Enrollment
110 (actual)
Sites
11

Conditions

As the registry lists them; a condition with its own page is linked.

aids-related hodgkin lymphoma, recurrent adult hodgkin lymphoma, recurrent follicular lymphoma, recurrent lymphoplasmacytic lymphoma, recurrent marginal zone lymphoma, recurrent non-hodgkin lymphoma, recurrent t-cell non-hodgkin lymphoma, waldenstrom macroglobulinemia